Stocks to Keep on the Watch List For April 3, 2017

The overall market looks like it will be opening higher this morning. However, nothing really exciting worth noting about. Seems like our usual, grind higher, non-eventful day. But that shouldn’t deter us. In fact, there are usually a couple symbols worth trading on any given day in the small cap space. Here are some that have caught our attention in the pre-market:

Dynavax Technologies Corporation (NASDAQ: DVAX) is up over 10% during pre-market trading due to its announcement of the U.S. Food and Drug Administration informing the company that the Vaccines and Related Biological Products Advisory Committee will review its Hepatitis B vaccine. DVAX had a pre-market high of $7.50 and a pre-market low of $6.15. Now, the stock has a 52-week range between $3.20 and $23.62, and it’s still over 65% below its 52 week high.

The stock recently broke above its 20- and 50-day SMAs, and this catalyst could cause the stock to fill the gap between the $6.95/$7.00 area and the $9.00 level.

BioCryst Pharmaceuticals, Inc (NASDAQ: BCRX) is up over 5% in the pre-market, after announcing that Mundipharma obtained regulator approval, from the Ministry of Health, Labor and Welfare in Japan, of its treatment of relapsed Peripheral T-Cell Lymphoma (PTCL). This would be the first country in the world to make Mundesine available for the treatment of PTCL, potentially generating higher revenues for the company.

BCRX hit a pre-market high of $9.25 and a pre-market low of $8.40. The stock is trading at the upper end of its 52-week range between $2.49 and $9.25. Now, the stock has been trading above its 20-, 50- and 200-day SMA, and after this news.

Syneron Medical Ltd (NASDAQ: ELOS) shares resumed for trading at 7:30 AM, after it announced its agreement to be acquired by funds advised by Apax Partners for $11.00 in a cash deal, an estimated value of $397M. ELOS hit a pre-market high of $12.75 and a pre-market low of $10.95, but the stock is trading closer to the $11 area now.

Akari Therapeutics PLC (NASDAQ: AKTX) shares were down just under 5% during pre-market trading. The stock hit a pre-market high of $12.25 and a pre-market low of $10.23. The company announced it would be presenting at the Jefferies Complement Symposium today. Additionally, the company filed a Form 20-F, after the close on Friday. Now, AKTX’s weak premarket trading could just be due to some good ole’ profit taking. The stock broke above its 20-, 50- and 200-day SMA on Friday, and its RSI rose above 85, potentially signaling some traders to take profits.

Infinity Pharmaceuticals Inc (NASDAQ: INFI) shares were up over 10% due to its updated Phase I data for its tumor treatment, which was well tolerated both alone and in combination with Bristol Myers Squibb’s Opdivo. INFI had a pre-market range between $3.41 and $3.91, at the time of this writing. Now, the stock has traded in a 52-week range between $0.84 and $6.63. INFI has recently broken above its 20-, 50- and 200-day SMA, and it’s been testing the 20-day SMA. However, after its Phase I data news, the stock could have a well-established uptrend.

Arotech Corporation (NASDAQ: ARTX) shares were trading higher by over 5% during the premarket, after the company received a follow-on contract for the U.S. Army’s Virtual Clearance Training Suite, worth $41.1M. ARTX hit a pre-market high of $3.55, and it could breakout of its recent downtrend. Now, the stock could break above its 20- and 200-day SMA today, which could signal a reversal of trend.

Here are some economic indicators you should focus on today:

  • PMI Manufacturing Index at 9:45 AM ET, the prior level was 54.2.
  • ISM Manufacturing Index at 10:00 AM ET, the previous level was 57.7, and the consensus estimate is 57.1, with a consensus range between 56.0 and 58.5
  • Construction Spending at 10:00 AM ET. The previous month-over-month change was -1.0%, and the consensus estimate is 1.0%, with a range between 0.7% and 1.8%.


Please enter your comment!
Please enter your name here